MedinCell Statistics
Total Valuation
MedinCell has a market cap or net worth of EUR 1.05 billion. The enterprise value is 1.04 billion.
| Market Cap | 1.05B |
| Enterprise Value | 1.04B |
Important Dates
The next estimated earnings date is Tuesday, December 9, 2025.
| Earnings Date | Dec 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MedinCell has 33.09 million shares outstanding. The number of shares has increased by 4.28% in one year.
| Current Share Class | 33.09M |
| Shares Outstanding | 33.09M |
| Shares Change (YoY) | +4.28% |
| Shares Change (QoQ) | +3.67% |
| Owned by Insiders (%) | 12.52% |
| Owned by Institutions (%) | 21.95% |
| Float | 25.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 37.72 |
| PB Ratio | -63.89 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 55.87 |
| P/OCF Ratio | 53.73 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -56.47 |
| EV / Sales | 37.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 55.63 |
Financial Position
The company has a current ratio of 2.70
| Current Ratio | 2.70 |
| Quick Ratio | 2.66 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | 3.60 |
| Interest Coverage | -2.12 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -10.56% |
| Return on Invested Capital (ROIC) | -17.98% |
| Return on Capital Employed (ROCE) | -17.77% |
| Revenue Per Employee | 211,656 |
| Profits Per Employee | -140,748 |
| Employee Count | 131 |
| Asset Turnover | 0.44 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, MedinCell has paid 160,000 in taxes.
| Income Tax | 160,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +64.33% in the last 52 weeks. The beta is 1.03, so MedinCell's price volatility has been similar to the market average.
| Beta (5Y) | 1.03 |
| 52-Week Price Change | +64.33% |
| 50-Day Moving Average | 27.37 |
| 200-Day Moving Average | 18.46 |
| Relative Strength Index (RSI) | 41.21 |
| Average Volume (20 Days) | 162,335 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MedinCell had revenue of EUR 27.73 million and -18.44 million in losses. Loss per share was -0.62.
| Revenue | 27.73M |
| Gross Profit | 27.73M |
| Operating Income | -10.76M |
| Pretax Income | -18.28M |
| Net Income | -18.44M |
| EBITDA | -10.07M |
| EBIT | -10.76M |
| Loss Per Share | -0.62 |
Balance Sheet
The company has 71.90 million in cash and 67.32 million in debt, giving a net cash position of 4.58 million or 0.14 per share.
| Cash & Cash Equivalents | 71.90M |
| Total Debt | 67.32M |
| Net Cash | 4.58M |
| Net Cash Per Share | 0.14 |
| Equity (Book Value) | -16.37M |
| Book Value Per Share | -0.49 |
| Working Capital | 50.74M |
Cash Flow
In the last 12 months, operating cash flow was 19.47 million and capital expenditures -747,000, giving a free cash flow of 18.72 million.
| Operating Cash Flow | 19.47M |
| Capital Expenditures | -747,000 |
| Free Cash Flow | 18.72M |
| FCF Per Share | 0.57 |
Margins
Gross margin is 100.00%, with operating and profit margins of -38.81% and -66.50%.
| Gross Margin | 100.00% |
| Operating Margin | -38.81% |
| Pretax Margin | -65.92% |
| Profit Margin | -66.50% |
| EBITDA Margin | -36.32% |
| EBIT Margin | -38.81% |
| FCF Margin | 67.51% |
Dividends & Yields
MedinCell does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.28% |
| Shareholder Yield | -4.28% |
| Earnings Yield | -1.76% |
| FCF Yield | 1.79% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MedinCell has an Altman Z-Score of 2.84 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.84 |
| Piotroski F-Score | 5 |